Autoimmune heart disease: role of sex hormones and autoantibodies in disease pathogenesis

References

• Roger VL, Go AS, Lloyd-Jones DM et al. Heart disease and stroke statistics – 2011 update: a report from the American Heart Association. Circulation104, 276–308 (2011).
   Google Scholar
• Jacobson DL, Gange SJ, Rose NR, Graham NMH. Epidemiology and estimated population burden of selected autoimmune disease in the United States. Clin. Immunol. Immunopathol.84, 223–243 (1997).
   PubMedGoogle Scholar
• Cooper LT Jr. Myocarditis. N. Engl. J. Med.360, 1526–1538 (2009).
   PubMed Web of Science ®Google Scholar
• McNamara DM, Starling RC, Cooper LT et al. Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy: results of the IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 study. J. Am. Coll. Cardiol.58, 1112–1118 (2011).
   PubMedGoogle Scholar
• Rubtsov A, Rubtsova K, Kappler JW, Marrack P. Genetic and hormonal factors in female-biased autoimmunity. Autoimm. Rev.9, 494–498 (2010).
   PubMedGoogle Scholar
• Nussinovitch U, Shoenfeld Y. Autoimmunity and heart diseases: pathogenesis and diagnostic criteria. Arch. Immunol. Ther. Exp.57, 95–104 (2009).
   PubMedGoogle Scholar
• Sherer Y, Shoenfeld Y. Mechanisms of disease: atherosclerosis in autoimmune disease. Nat. Clin. Pract. Rheum.2, 99–106 (2006).
   PubMedGoogle Scholar
• Lago F, Gomez R, Conde J, Scotece M, Gomez-Reino JJ, Gualillo O. Cardiometabolic co-morbidities and rheumatic diseases: focus on the role of fat mass and adipokines. Arthritis Care Res. (Hoboken)63, 1083–1090 (2011).
   PubMed Web of Science ®Google Scholar
• Haque S, Gordon C, Isenberg D et al. Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study. J. Rheumatol.37, 322–329 (2010).
   PubMed Web of Science ®Google Scholar
• Urowitz MB, Gladman D, Ibanez D et al. Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res.62, 881–887 (2010).
   PubMed Web of Science ®Google Scholar
• Symmons DPM, Gabriel SE. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat. Rev. Rheumatol.7, 399–408 (2011).
   PubMed Web of Science ®Google Scholar
• Lu L-J, Wallace DJ, Ishimori ML, Scofield RH, Weisman MH. Male systemic lupus erythematosus: a review of sex disparities in this disease. Lupus19, 119–129 (2010).
   PubMed Web of Science ®Google Scholar
• Agmon-Levin N, Mosca M, Petri M, Shoenfeld Y. Systemic lupus erythematosus one disease or many? Autoimmun. Rev. doi:10.1016/j.autrev.2011.10.020 (2011) (Epub ahead of print).
   Google Scholar
• Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in northern Sweden. J. Rheumatol.24, 445–451 (1997).
   PubMed Web of Science ®Google Scholar
• Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthitis Rheum.59, 1690–1697 (2008).
   PubMed Web of Science ®Google Scholar
• Innala L, Moller B, Ljung L et al. Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study. Arthritis Res. Ther.13, R131 (2011).
   Web of Science ®Google Scholar
• Kallwellis-Opara A, Dorner A, Poller WC et al. Autoimmunological features in inflammatory cardiomyopathy. Clin. Res. Cardiol.96, 469–480 (2007).
   PubMedGoogle Scholar
• Fairweather D, Frisancho-Kiss S, Rose NR. Sex differences in autoimmune disease from a pathologic perspective. Am. J. Pathol.173, 600–609 (2008).
   PubMed Web of Science ®Google Scholar
• Vitale C, Mendelsohn ME, Rosano GMC. Gender differences in the cardiovascular effect of sex hormones. Nat. Rev. Cardiol.6, 532–542 (2009).
   PubMed Web of Science ®Google Scholar
• Regitz-Zagrosek V, Oertelt-Prignione S, Seeland U, Hetzer R. Sex and gender differences in myocardial hypertrophy and heart failure. Circ. J.74, 1265–1273 (2010).
   PubMed Web of Science ®Google Scholar
• Kaushik M, Sontineni SP, Hunter C. Cardiovascular disease and androgens: a review. Int. J. Cardiol.142, 8–14 (2010).
   PubMed Web of Science ®Google Scholar
• Lee LV, Foody JM. Women and heart disease. Cardiol. Clin.29, 35–45 (2011).
   PubMedGoogle Scholar
• Tan YY, Gast GM, van der Schouw YT. Gender differences in risk factors for coronary heart disease. Maturitas65, 149–160 (2010).
   PubMed Web of Science ®Google Scholar
• Blauwet LA. Sex and race/ethnicity reporting in clinical trials: a necessity, not an option. J. Women’s Health20, 313–314 (2011).
   PubMedGoogle Scholar
• Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science308, 1583–1587 (2005).
   PubMed Web of Science ®Google Scholar
• Legato MJ, Leghe JK. Gender and the heart: sex-specific differences in the normal myocardial anatomy and physiology. In: Principles of Gender-Specific Medicine (2nd Edition). Legato MJ (Ed.). Elsevier, MA, USA, 151–161 (2010).
   Google Scholar
• Isensee J, Ruiz, Noppinger P. Sexually dimorphic gene expression in mammalian somatic tissue. Gend. Med.4(Suppl. B), S75–S95 (2007).
   PubMedGoogle Scholar
• Lahita RG. Sex hormones and immune function. In: Principles of Gender-Specific Medicine (2nd Edition). Legato MJ (Ed.). Elsevier, MA, USA, 615–626 (2010).
   Google Scholar
• Regitz-Zagrosek V, Becher E, Mahmoodzadeh S, Schubert C. Sex steroid hormones. In: Cardiovascular Hormone Systems: From Molecular Mechanisms to Novel Therapeutics. Bader M (Ed.). Wiley-Blackwell, Weinheim, Germany, 39–64 (2008).
   Google Scholar
• Cutolo M. Hormones and cytokines: gender-specific effects. In: Principles of Gender-Specific Medicine (2nd Edition). Legato MJ (Ed.). Elsevier, MA, USA, 592–596 (2010).
   Google Scholar
• Straub RH. The complex role of estrogens in inflammation. Endocrine Rev.28, 521–574 (2007).
   PubMed Web of Science ®Google Scholar
• Cook IF. Sexual dimorphism of humoral immunity with vaccines. Vaccine26, 3551–3555 (2008).
   PubMed Web of Science ®Google Scholar
• Carreras E, Turner S, Frank MB et al. Estrogen receptor signaling promotes dendritic cell differentiation by increasing expression of the transcription factor IRF4. Blood115, 238–246 (2010).
   PubMed Web of Science ®Google Scholar
• Khan D, Dai R, Karpuzoglu E, Ahmed SA. Estrogen increases, whereas IL-27 and IFN-gamma decrease, splenocyte IL-17 production in WT mice. Eur. J. Immunol.40, 2549–2556 (2010).
   PubMedGoogle Scholar
• Wang Y, Cela E, Gagnon S, Sweezey NB. Estrogen aggravates inflammation in Pseudomonas aeruginosa pneumonia in cystic fibrosis mice. Respir. Res.30, 166 (2010).
   Google Scholar
• Xia X, Zhang S, Yu Y et al. Effects of estrogen replacement therapy on estrogen receptor expression and immunoregulatory cytokine secretion in surgically induced menopausal women. J. Reprod. Immunol.81, 89–96 (2009).
   PubMed Web of Science ®Google Scholar
• Pulendran B, Tang H, Manicassamy S. Programming dendritic cells to induce Th2 and tolergenic responses. Nat. Immunol.11, 647–655 (2010).
   PubMed Web of Science ®Google Scholar
• Dinesh RK, Hahn BH, Singh RP. PD-1, gender and autoimmunity. Autoimm. Rev.9, 583–587 (2010).
   PubMed Web of Science ®Google Scholar
• Sellner J, Kraus J, Awad A, Milo R, Hemmer B, Stuve O. The increasing incidence and prevalence of female multiple sclerosis – a critical analysis of potential environmental factors. Autoimm. Rev.10, 495–502 (2011).
   PubMed Web of Science ®Google Scholar
• Papenfuss TL, Powell ND, McClain MA et al. Estriol generates tolergenic dendritic cells in vivo that protect against autoimmunity. J. Immunol.186, 3346–3355 (2011).
   PubMed Web of Science ®Google Scholar
• Frisancho-Kiss S, Davis SE, Nyland JF et al. Cutting edge: cross-regulation by TLR4 and T cell Ig mucin-3 determines sex differences in inflammatory heart disease. J. Immunol.178, 6710–6714 (2007).
   PubMedGoogle Scholar
• Giron-Gonzalez JA, Moral FJ, Elvira J et al. Consistent production of a higher TH1:TH2 cytokine ratio by stimulated T cells in men compared to women. Eur. J. Endocrinol.143, 31–36 (2000).
   PubMed Web of Science ®Google Scholar
• Frisancho-Kiss S, Coronado MJ, Frisancho JA et al. Gonadectomy of male BALB/c mice increases Tim-3+ alternatively activated M2 macrophages, Tim-3+ T cells, Th2 cells and Treg in the heart during acute coxsackievirus-induced myocarditis. Brain Behav. Immun.23, 649–657 (2009).
   PubMed Web of Science ®Google Scholar
• Onyimba JA, Coronado MJ, Garton AE et al. The innate immune response to coxsackievirus B3 predicts progression to cardiovascular disease and heart failure in male mice. Biol. Sex Differ.2, 2 (2011).
   PubMedGoogle Scholar
• Curtiss LK, Tobias PS. Emerging role of Toll-like receptors in atherosclerosis. J. Lipid Res.50, S340–S345 (2009).
   PubMedGoogle Scholar
• Teuscher C, Noubade R, Spach K et al. Evidence that the Y chromosome influences autoimmune disease in male and female mice. Proc. Natl. Acad. Sci. USA103, 8024–8029 (2006).
   PubMedGoogle Scholar
• Ozcelik T. X chromosome inactivation and female predisposition to autoimmunity. Clinic Rev. Allerg. Immunol.34, 348–351 (2008).
   PubMedGoogle Scholar
• Selmi C. The X in sex: how autoimmune diseases revolve around sex chromosomes. Best Pract. Res. Clin. Rheum.22, 913–922 (2008).
   PubMed Web of Science ®Google Scholar
• Arnold AP, Chen X. What does the “four core genotypes” mouse model tell us about sex differences in the brain and other tissues? Front. Neuroendocrinol.30, 1–9 (2009).
   PubMed Web of Science ®Google Scholar
• Lemos B, Branco AT, Hartl DL. Epigenetic effects of polymorphic Y chromosomes modulate chromatin components, immune response, and sexual conflict. Proc. Natl. Acad. Sci. USA107, 15826–15831 (2010).
   PubMedGoogle Scholar
• Faulk C, Dolinoy DC. Timing is everything: the when and how of environmentally induced changes in the epigenome of animals. Epigenetics6, 791–797 (2011).
   PubMed Web of Science ®Google Scholar
• Renaudineau Y, Youinou P. Epigenetics and autoimmunity, with special emphasis on methylation. Keio. J. Med.60, 10–16 (2011).
   PubMedGoogle Scholar
• Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat. Immunol.12, 204–212 (2011).
   PubMed Web of Science ®Google Scholar
• Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature473, 317–325 (2011).
   PubMed Web of Science ®Google Scholar
• White HD, Chew DP. Acute myocardial infarction. Lancet372, 570–584 (2008).
   PubMed Web of Science ®Google Scholar
• Laczik R, Szodoray P, Veres K et al. Assessment of IgG antibodies to oxidized LDL in patients with acute coronary syndrome. Lupus20, 730–735 (2011).
   PubMedGoogle Scholar
• Shi G-P. Immunomodulation of vascular diseases: atherosclerosis and autoimmunity. Eur. J. Vasc. Endovasc. Surg.39, 485–494 (2010).
   PubMedGoogle Scholar
• Dart ML, Jankowska-Gan E, Huang G et al. Interleukin-17-dependent autoimmunity to collagen type V in atherosclerosis. Circ. Res.107, 1106–1116 (2010).
   PubMed Web of Science ®Google Scholar
• Bergmark C, Wu R, de Faire U, Lefvert AK, Swedenborg J. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler. Thromb. Vasc. Biol.15, 441–445 (1995).
   PubMed Web of Science ®Google Scholar
• Greco TP, Conti-Kelly AM, Anthony JR et al. Oxidized-LDL/beta(2)-glycoprotein I complexes are associated with disease severity and increased risk for adverse outcomes in patients with acute coronary syndromes. Am. J. Clin. Pathol.133, 737–743 (2010).
   PubMedGoogle Scholar
• Ait-Oufella H, Salomon BL, Potteaux S et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat. Med.12, 178–180 (2006).
   PubMed Web of Science ®Google Scholar
• Van Leeuwen M, Damoiseaux J, Duijvestijn A, Cohen JW, Cohen Tervaert JW. The therapeutic potential of targeting B cells and anti-oxLDL antibodies in atherosclerosis. Autoimm. Rev.9, 53–57 (2009).
   PubMedGoogle Scholar
• Bjorkbacka H, Kunjathoor VV, Moore KJ et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat. Med.10, 416–421 (2004).
   PubMed Web of Science ®Google Scholar
• Kirii H, Niwa T, Yamada Y et al. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol.23, 656–660 (2003).
   PubMed Web of Science ®Google Scholar
• Elhage R, Jawien J, Rudling M et al. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc. Res.59, 234–240 (2003).
   PubMed Web of Science ®Google Scholar
• Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by Toll-like receptor 2. J. Clin. Invest.115, 3149–3156 (2005).
   PubMed Web of Science ®Google Scholar
• Michelsen KS, Wong MH, Shah PK et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc. Natl. Acad. Sci. USA101, 10679–10684 (2004).
   PubMed Web of Science ®Google Scholar
• Sakao S, Tanabe N, Tatsumi K. The estrogen paradox in pulmonary arterial hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol.299, L435–L438 (2010).
   Google Scholar
• Regitz-Zagrosek V. Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nat. Rev. Drug Discov.5, 425–438 (2006).
   PubMed Web of Science ®Google Scholar
• Villablanca AC, Jayachandran M, Banka C. Atherosclerosis and sex hormones: current concepts. Clin. Sci.119, 493–513 (2010).
   PubMed Web of Science ®Google Scholar
• McCrohon JA, Death AK, Nakhla S et al. Androgen receptor expression is greater in macrophages from male than from female donors. A sex difference with implications for atherogenesis. Circulation101, 224–226 (2000).
   PubMed Web of Science ®Google Scholar
• Wilson ME, Sengoku T, Allred KF. Estrogen prevents cholesteryl ester accumulation in macrophages induced by the HIV protease inhibitor ritonavir. J. Cell Biochem.103, 1598–1606 (2008).
   PubMed Web of Science ®Google Scholar
• Badeau RM, Metso J, Wahala K, Tikkanen MJ, Jauhiainen M. Human macrophage cholesterol efflux potential is enhanced by HDL-associated 17beta-estradiol fatty acyl esters. J. Steroid Biochem. Mol. Biol.116, 44–49 (2009).
   PubMedGoogle Scholar
• Hodgin JB, Krege JH, Reddick RL, Korach KS, Smithies O, Maeda N. Estrogen receptor alpha is a major mediator of 17beta-estradiol’s atheroprotective effects on lesion size in Apoe-/- mice. J. Clin. Invest.107, 333–340 (2001).
   PubMed Web of Science ®Google Scholar
• Deshpande R, Khalili H, Pergolizzi RG, Michael SD, Change MD. Estradiol down-regulates LPS-induced cytokine production and NFκB activation in murine macrophages. Am. J. Reprod. Immunol.38, 46–54 (1997).
   PubMed Web of Science ®Google Scholar
• Evans MJ, Eckert A, Lai K, Adelman SJ, Harnish DC. Reciprocal antagonism between estrogen receptor and NF-kappaB activity in vivo. Circ. Res.89, 823–830 (2001).
   PubMed Web of Science ®Google Scholar
• Miller MA, Strazzullo P, Karanam S, Cappuccio FP. Ethnic variation in levels of circulation IgG autoantibodies to oxidized low-density lipoprotein. Atherosclerosis203, 126–136 (2009).
   PubMedGoogle Scholar
• Von Dehn G, von Dehn O, Volker W et al. Atherosclerosis in apolipoprotein E-deficient mice is decreased by the suppression of endogenous sex hormones. Horm. Metab. Res.33, 110–114 (2001).
   PubMedGoogle Scholar
• English KM, Mandour O, Steeds RP, Diver MJ, Jones TH, Channer KS. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur. Heart J.21, 890–894 (2000).
   PubMed Web of Science ®Google Scholar
• Wexler RK, Elton T, Pleister A, Feldman D. Cardiomyopathy: an overview. Am. Fam. Physician.79, 778–784 (2009).
   PubMed Web of Science ®Google Scholar
• Grzybowski J, Bilinska ZT, Ruzyllo W et al. Determinants of prognosis of nonischemic dilated cardiomopathy. J. Card. Fail.2, 77–85 (1996).
   PubMedGoogle Scholar
• Gupta S, Markham DW, Drazner MH, Mammen PPA. Fulminant myocarditis. Nat. Clin. Practice5, 693–706 (2008).
   Google Scholar
• Schultheiss HP, Kuhl U, Cooper LT. The management of myocarditis. Eur. Heart J.32, 2616–2625 (2011).
   PubMed Web of Science ®Google Scholar
• Blauwet LA, Cooper LT. Myocarditis. Prog. Cardiovasc. Dis.52, 274–288 (2010).
   PubMed Web of Science ®Google Scholar
• Schultheiss HP, Kuhl U. Why is diagnosis of infectious myocarditis such a challenge? Expert Rev. Anti Infect. Ther.9(12), 1093–1095 (2011).
   PubMed Web of Science ®Google Scholar
• Andreoletti L, Venteo L, Douche-Aourik F et al. Active coxsackieviral B infection is associated with disruption of dystrophin in endomyocardial tissue of patients who died suddenly of acute myocardial infarction. J. Am. Coll. Cardiol.50, 2207–2214 (2007).
   PubMed Web of Science ®Google Scholar
• Huber SA. Autoimmunity in coxsackievirus B3 induced myocarditis. Autoimmunity39, 55–61 (2006).
   PubMed Web of Science ®Google Scholar
• Fairweather D, Rose NR. Coxsackievirus-induced myocarditis in mice: a model of autoimmune disease for studying immunotoxicity. Methods41, 118–122 (2007).
   PubMed Web of Science ®Google Scholar
• Ellis NM, Kurahara DK, Vohra H et al. Priming the immune system for heart disease: a perspective on group A streptococci. J. Infect. Dis.202, 1059–1067 (2010).
   PubMed Web of Science ®Google Scholar
• Huber SA, Job LP. Cellular immune mechanisms in coxsackievirus group B, type 3 induced myocarditis in BALB/c mice. Adv. Exp. Med. Biol.161, 491–508 (1983).
   PubMedGoogle Scholar
• Cihakova D, Barin JG, Afanasyeva M et al. Interleukin-13 protects against experimental autoimmune myocarditis by regulating macrophage differentiation. Am. J. Pathol.172, 1195–1208 (2008).
   PubMed Web of Science ®Google Scholar
• Fairweather D, Kaya Z, Shellam GR, Lawson CM, Rose NR. From infection to autoimmunity. J. Autoimm.16, 175–186 (2001).
   PubMed Web of Science ®Google Scholar
• Huber SA, Sartini D, Exley M. Vgamma4(+) T cells promote autoimmune CD8(+) cytolytic T-lymphocyte activation in coxsackievirus B3-induced myocarditis in mice: role for CD4(+) Th1 cells. J. Virol.76, 10785–10790 (2002).
   PubMedGoogle Scholar
• Huber SA. T lymphocytes kill T regulatory cells through CD1d. Immunology131, 202–209 (2010).
   PubMedGoogle Scholar
• Frisancho-Kiss S, Nyland JF, Davis SE et al. Cutting Edge: T cell Ig mucin-3 reduces inflammatory heart disease by increasing CTLA-4 during innate immunity. J. Immunol.176, 6411–6415 (2006).
   PubMed Web of Science ®Google Scholar
• Fairweather D, Cihakova D. Alternatively activated macrophages in infection and autoimmunity. J. Autoimm.33, 222–230 (2009).
   PubMed Web of Science ®Google Scholar
• Huber SA. Cd1d expression on hemopoietic cells promotes CD4+ Th1 response in coxsackievirus B3 induced myocarditis. Virology352, 226–236 (2006).
   PubMedGoogle Scholar
• Noutsias M, Rohde M, Goldner K et al. Expression of functional T-cell markers and T-cell receptor Vbeta repertoire in endomyocardial biopsies from patients presenting with acute myocarditis and dilated cardiomyopathy. Eur. J. Heart Fail.13, 611–618 (2011).
   PubMedGoogle Scholar
• Yuan J, Cao AL, Yu M et al. Th17 cells facilitate the humoral immune response in patients with acute viral myocarditis. J. Clin. Immunol.30, 226–234 (2010).
   PubMed Web of Science ®Google Scholar
• Baldeviano GC, Barin JG, Talor MV et al. Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy. Circ. Res.106, 1646–1655 (2010).
   PubMed Web of Science ®Google Scholar
• Abston ED, Coronado MJ, Bucek A et al. Th2 regulation of viral myocarditis in mice: different roles for TLR3 vs. TRIF in progression to chronic disease. Clin. Dev. Immunol.2012, 129486 (2012).
   PubMedGoogle Scholar
• Mann DL. The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circ. Res.108, 1133–1145 (2011).
   PubMed Web of Science ®Google Scholar
• Lane JR, Neumann DA, Lafond-Walker A, Herskowitz A, Rose NR. LPS promotes CB3-induced myocarditis in resistant B10.A mice. Cell. Immunol.136, 219–233 (1991).
   PubMedGoogle Scholar
• Fairweather D, Yusung S, Frisancho S et al. IL-12Rβ1 and TLR4 increase IL-1β and IL-18-associated myocarditis and coxsackievirus replication. J. Immunol.170, 4731–4737 (2003).
   PubMed Web of Science ®Google Scholar
• Cain BS, Meldrum DR, Dinarello CA et al. Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. Crit. Care Med.27, 1309–1318 (1999).
   PubMed Web of Science ®Google Scholar
• Blyszczuk P, Kania G, Dieterle T et al. Myeloid differentiation factor88/ interleukin-1 signaling controls cardiac fibrosis and heart failure progression in inflammatory dilated cardiomyopathy. Circ. Res.105, 912–920 (2009).
   PubMedGoogle Scholar
• Vallejo JG. Role of Toll-like receptors in cardiovascular diseases. Clin. Sci.121, 1–10 (2011).
   PubMed Web of Science ®Google Scholar
• Zhang P, Cox CJ, Alvarez KM, Cunningham MW. Cutting edge: cardiac myosin activates innate immune responses through TLRs. J. Immunol.183, 27–31 (2009).
   PubMed Web of Science ®Google Scholar
• Satoh M, Nakamura M, Akatsu T et al. Expression of Toll-like receptor 4 is associated with enteroviral replication in human myocarditis. Clin. Sci. (London)104, 577–584 (2003).
   PubMed Web of Science ®Google Scholar
• Fairweather D, Frisancho-Kiss S, Yusung SA et al. IFN-γ protects against chronic viral myocarditis by reducing mast cell degranulation, fibrosis, and the profibrotic cytokines TGF-β1, IL-1β, and IL-4 in the heart. Am. J. Pathol.165, 1883–1894 (2004).
   PubMed Web of Science ®Google Scholar
• Fairweather D, Frisancho-Kiss S, Njoku DB et al. Complement receptor 1 and 2 deficiency increases coxsackievirus B3-induced myocarditis and heart failure by increasing macrophages, IL-1β and immune complex deposition in the heart. J. Immunol.176, 3516–3524 (2006).
   PubMedGoogle Scholar
• Nishikubo K, Imanaka-Yoshida K, Tamaki S et al. Th1-type immune responses by Toll-like receptor 4 signaling are required for the development of myocarditis in mice with BCG-induced myocarditis. J. Autoimm.29, 146–153 (2007).
   PubMedGoogle Scholar
• Gorbea C, Makar KA, Pauschinger M et al. A role for Toll-like receptor 3 variants in host susceptibility to enteroviral myocarditis and dilated cardiomyopathy. J. Biol. Chem.285, 23208–23223 (2010).
   PubMed Web of Science ®Google Scholar
• Riad A, Westermann D, Escher F et al. Myeloid differentiation factor-88 contributues to TLR9-mediated modulation of acute coxsackievirus B3-induced myocarditis in vivo. Am. J. Physiol. Heart Circ. Physiol.298, H2024–H2031 (2010).
   Google Scholar
• Pagni PP, Truab S, Demaria O, Chasson L, Alexopoulou L. Contribution of TLR7 and TLR9 signaling to the susceptibility of MyD88-deficient mice to myocarditis. Autoimmunity43, 275–287 (2010).
   PubMed Web of Science ®Google Scholar
• Riad A, Westermann D, Zietsch C et al. TRIF is a critical survival factor in viral cardiomyopathy. J. Immunol.186, 2561–2570 (2011).
   PubMed Web of Science ®Google Scholar
• Huber SA, Job LP, Woodruff JF. Sex-related differences in the pattern of coxsackievirus B3-induced immune spleen cell cytotoxicity against virus-infected myofibers. Infect. Immun.32, 68–73 (1981).
   PubMedGoogle Scholar
• Robinson DP, Huber SA, Moussawi M et al. Sex chromosome complement contributes to sex differences in coxsackievirus B3 but not influenza A virus pathogenesis. Biol. Sex Differ.2, 8 (2011).
   PubMedGoogle Scholar
• Huber SA. Increased susceptibility of male BALB/c mice to coxsackievirus B3-induced myocarditis: role for CD1d. Med. Microbiol. Immunol.194, 121–127 (2005).
   PubMed Web of Science ®Google Scholar
• Huber SA. Coxsackievirus B3-induced mycoarditis: infection of females during the estrus phase of the ovarian cycle leads to activation of T regulatory cells. Virology378, 292–298 (2008).
   PubMed Web of Science ®Google Scholar
• Li K, Xu W, Guo Q et al. Differential macrophage polarization in male and female BALB/c mice infected with coxsackievirus B3 defines susceptibility to viral myocarditis. Circ. Res.105, 353–364 (2009).
   PubMed Web of Science ®Google Scholar
• Frisancho-Kiss S, Nyland JF, Davis SE et al. Sex differences in coxsackievirus B3-induced myocarditis: IL-12Rbeta1 signaling and IFN-gamma increase inflammation in males independent from STAT4. Brain Res.1126, 139–147 (2006).
   PubMed Web of Science ®Google Scholar
• Kindermann I, Kindermann N, Kandolf R et al. Predictors of outcome in patients with suspected myocarditis. Circulation118, e493 (2008).
   Google Scholar
• Cocker MS, Abdel-Aty H, Strohm O, Friedrich MG. Age and gender effects on the extent of myocardial involvement in acute myocarditis: a cardiovascular magnetic resonance study. Heart95, 1925–1930 (2009).
   PubMed Web of Science ®Google Scholar
• Cavasin MA, Tao ZY, Yu AL, Yang XP. Testosterone enhances early cardiac remodeling after myocardial infarction, causing rupture and degrading cardiac function. Am. J. Physiol. Heart Circ. Physiol.290, H2043–H2050 (2006).
   PubMed Web of Science ®Google Scholar
• Wolfgram LJ, Beisel KW, Rose NR. Heart-specific autoantibodies following murine coxsackievirus B3 myocarditis. J. Exp. Med.161, 1112–1121 (1985).
   PubMed Web of Science ®Google Scholar
• Fairweather D, Abston ED, Coronado MJ. Biomarkers of heart failure in myocarditis and dilated cardiomyopathy. In: Myocarditis. Cihakova D (Ed.). InTech Open Access Publisher, Rijeka, Croatia, 323–348 (2011).
   Google Scholar
• Nussinovitch U, Shoenfeld Y. The clinical significance of anti-beta-1 adrenergic receptor autoantibodies in cardiac disease. Clin. Rev. Allergy Immunol. doi:10.1007/s12016-010-8228-9 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Nussinovitch U, Shoenfeld Y. The clinical and diagnostic significance of anti-myosin autoantibodies in cardiac disease. Clin. Rev. Allergy Immunol. doi:10.1007/s12016-010-8229-8 (2011) (Epub ahead of print).
   Google Scholar
• Nussinovitch U, Shoenfeld Y. The diagnostic and clinical significance of anti-muscarinic receptor autoantibodies. Clin. Rev. Allergy Immunol. doi:10.1007/s12016-010-8235 (2011) (Epub ahead of print).
   Google Scholar
• Limas CJ, Goldenberg IF, Limas C. Autoantibodies against beta-adrenoreceptors in human idiopathic dilated cardiomyopathy. Circ. Res.64, 97–103 (1989).
   PubMed Web of Science ®Google Scholar
• Mascaro-Blanco A, Alvarez K, Yu X et al. Consequences of unlocking the cardiac myosin molecule in human myocarditis and cardiomyopathies. Autoimmunity41, 442–453 (2008).
   PubMed Web of Science ®Google Scholar
• Jahns R, Boivin V, Hein L et al. Direct evidence for a beta 1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J. Clin. Invest.113, 1419–1429 (2004).
   PubMed Web of Science ®Google Scholar
• Robinson T, Smith A, Channer KS. Reversible heart failure: the role of inflammatory activation. Postgrad. Med. J.87, 110–115 (2011).
   PubMedGoogle Scholar
• Wang Y-X, da Cunha V, Vincelette J et al. Antiviral and myocyte protective effects of murine interferon-β and -α2 in coxsackievirus B3-induced myocarditis and epicarditis in BALB/c mice. Am. J. Physiol. Heart Circ. Physiol.293, H69–H76 (2007).
   PubMed Web of Science ®Google Scholar
• Regitz-Zagrosek V, Seeland U. Sex and gender differences in myocardial hypertrophy and heart failure. Wien Med. Wochenschr.161, 109–116 (2011).
   PubMedGoogle Scholar
• Murphy E, Steenbergen C. Cardioprotection in females: a role for nitric oxide and altered gene expression. Heart Fail. Rev.12, 293–300 (2007).
   PubMed Web of Science ®Google Scholar
• The Autoimmune Diseases Coordinating Committee. Progress in Autoimmune Disease Research, Report to Congress. National Institutes of Health, DC, USA (2005).
   Google Scholar
• Zandman-Goddard G, Peeva E, Shoenfeld Y. Gender and autoimmunity. Autoimm. Rev.6, 366–372 (2007).
   PubMed Web of Science ®Google Scholar
• McCombe PA, Greer JM, Mackay IR. Sexual dimorphism in autoimmune disease. Curr. Mol. Med.9, 1058–1079 (2009).
   PubMed Web of Science ®Google Scholar
• Brooks WH, Le Dantec C, Pers JO, Youinou P, Renaudineau Y. Epigenetics and autoimmunity. J. Autoimmun.34, J207–J219 (2010).
   PubMed Web of Science ®Google Scholar
• Toms TE, Panoulas VF, Kitas GD. Dyslipidaemia in rheumatological autoimmune diseases. Open Cardiov. Med. J.5, 64–75 (2011).
   PubMedGoogle Scholar
• Kung M, Stork S, Angermann CE. Cardiovascular comorbidity in rheumatic disease. Does sex play a role? Herz30, 512–521 (2005).
   PubMedGoogle Scholar
• Petri M. Sex hormones and systemic lupus erythematosus. Lupus17, 412–415 (2008).
   PubMed Web of Science ®Google Scholar
• Weckerle CE, Niewold TB. The unexplained female predominance of systemic lupus erythematosus: clues from genetic and cytokine studies. Clinic. Rev. Allerg. Immunol.40, 42–49 (2011).
   PubMed Web of Science ®Google Scholar
• Petri M. Systemic lupus erythematosus: 2006 update. J. Clin. Rheumatol.12, 37–40 (2006).
   PubMed Web of Science ®Google Scholar
• Gualtierotti R, Biggioggero M, Penatti AE, Meroni PL. Updating on the pathogenesis of systemic lupus erythematosus. Autoimm. Rev.10, 3–7 (2010).
   PubMed Web of Science ®Google Scholar
• Abdou NI, Rider V. Gender differences in autoimmune diseases: immune mechanisms and clinical applications. In: Principles of Gender-Specific Medicine (2nd Edition). Legato MJ (Ed.). Elsevier, MA, USA, 858–591 (2010).
   Google Scholar
• Wang J, Nuite M, McAlindon TE. Association of estrogen and aromatase gene polymorphisms with systemic lupus erythematosus. Lupus19, 734–740 (2010).
   PubMedGoogle Scholar
• Lu L-J, Wallace DJ, Ishimori ML, Scofield RH, Weisman MH. Male systemic lupus erythematosus: a review of sex disparities in this disease. Lupus19, 119–129 (2010).
   PubMed Web of Science ®Google Scholar
• Niewold TB, Adler JE, Glenn SB, Lehman TJ, Harley JB, Crow MK. Age- and sex-related patterns of serum interferon-alpha activity in lupus families. Arthritis Rheum.58, 2113–2119 (2008).
   PubMedGoogle Scholar
• Ronnblom L, Alm GV, Eloranta ML. Type I interferon and lupus. Curr. Opin. Rheumatol.21, 471–477 (2009).
   PubMed Web of Science ®Google Scholar
• Siracusa MC, Overstreet MG, Housseau F, Scott AL, Klein SL. 17beta-estradiol alters the activity of conventional and IFN-producing killer dendritic cells. J. Immunol.180, 1423–1431 (2008).
   PubMedGoogle Scholar
• Szalay G, Sauter M, Haberland M et al. Osteopontin: a fibrosis-related marker molecule in cardiac remodeling of enterovirus myocarditis in the susceptible host. Circ. Res.104, 851–859 (2009).
   PubMed Web of Science ®Google Scholar
• Kariuki SN, Moore JG, Kirou KA, Crow MK, Utset TO, Niewold TB. Age- and gender-specific modulation of serum osteopontin and interferon-alpha by osteopontin genotype in systemic lupus erythematosus. Genes Immun.10, 487–494 (2009).
   PubMedGoogle Scholar
• Doria A, Iaccarino L, Sarzi-Puttini P, Atzeni F, Turriel M, Petri M. Cardiac involvement in systemic lupus erythematosus. Lupus14, 683–686 (2005).
   PubMed Web of Science ®Google Scholar
• Crosslin KL, Wiginton KL. Sex differences in disease severity among patients with systemic lupus erythematosus. Gend. Med.8, 365–371 (2011).
   PubMedGoogle Scholar
• Kiani AN, Magder L, Petri M. Coronary calcium in systemic lupus erythamatosus is associated with traditional cardiovascular risk factors, but not with disease activity. J. Rheumatol.35, 1300–1306 (2008).
   PubMed Web of Science ®Google Scholar
• Karp I, Abrahamowicz M, Fortin PR et al. Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus? Arthritis Rheum.59, 169–175 (2008).
   PubMedGoogle Scholar
• Petri MA, Kiani AN, Christopher-Stine L, Magder LS. Lupus atherosclerosis prevention study (LAPS). Ann. Rheum. Dis.70(5), 760–765 (2011).
   PubMed Web of Science ®Google Scholar
• Ashrafi R, Garg P, McKay E, Gosney J, Chuah S, Davis G. Aggressive cardiac involvement in systemic lupus erythematosus: a case report and a comprehensive literature review. Cardiol. Res. Pract.2011, 578390 (2011).
   PubMedGoogle Scholar
• Ippolito A, Petri M. An update on mortality in systemic lupus erythematosus. Clin. Exp. Rheumatol.26(5 Suppl. 51), S72–S79 (2008).
   PubMed Web of Science ®Google Scholar
• Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb. Res.114, 593–595 (2004).
   PubMed Web of Science ®Google Scholar
• Van Venrooij WJ, van Beers JJBC, Pruijn GJM. Anti-CCP antibodies: the past, the present and the future. Nat. Rev. Rheumatol.7, 391–398 (2011).
   PubMed Web of Science ®Google Scholar
• Steiner G, Urowitz M. Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. Semin. Arthritis Rheum.38, 372–381 (2009).
   PubMed Web of Science ®Google Scholar
• Bartoloni E, Alunno A, Luccioli F et al. Atherosclerotic vascular damage and rheumatoid arthritis: a complex but intriguing link. Expert Rev. Cardiovasc. Ther.8, 1309–1316 (2010).
   PubMedGoogle Scholar
• Nielsen RH, Christiansen C, Stolina M, Karsdal MA. Oestrogen exhibits type II collagen protective effects and attenuates collagen-induced arthritis in rats. Clin. Exp. Immunol.152, 21–27 (2008).
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Houbiers JG, Buttgereit F et al. The selective estrogen receptor alpha agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity: a Phase IIa trial investigating efficacy and safety of Org 37663 in postmenopausal female rheumatoid arthritis patients receiving stable background methotrexate or sulfasalazine. Arthitis Rheum.62, 351–358 (2010).
   PubMed Web of Science ®Google Scholar
• Cutolo M. Selective estrogen receptor agonism lacks clinical benefit in rheumatoid arthritis: comment on the article by van Vollenhoven et al. Arthitis Rheum.62, 3832–3833 (2010).
   PubMedGoogle Scholar
• Castagnetta LA, Carruba G, Franata OM et al. Increased estrogen formation and estrogen to androgen ratio in the synovial fluid of patients with rheumatoid arthritis. J. Rheumatol.30, 2597–2605 (2003).
   PubMed Web of Science ®Google Scholar
• Olsen NJ, Kovacs WJ. Hormones, pregnancy and rheumatoid arthritis. J. Gend. Specif. Med.5, 28–37 (2002).
   PubMedGoogle Scholar
• Kramer HR, Giles JT. Cardiovascular disease risk in rheumatoid arthritis: progress, debate, and opportunity. Arthritis Care Res.63, 484–499 (2011).
   PubMed Web of Science ®Google Scholar
• Dixon WG, Watson KD, Lunt M et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthitis Rheum.56, 2905–2912 (2007).
   PubMed Web of Science ®Google Scholar
• Cihakova D, Talor MV, Barin JG et al. Sex differences in a murine model of Sjorgren syndrome. Ann. N.Y. Acad. Sci.1173, 378–383 (2009).
   PubMedGoogle Scholar
• Baldini C, Tlarico R, Tzioufas AG, Bombardieri S. Classification criteria for Sjögren’s syndrome: a critical review. J. Autoimm. doi:10.1016/j.jaut.2011.12.006 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Defendenti C, Atzeni F, Spina MF et al. Clinical and laboratory aspects of Ro/SSA-52 autoantibodies. Autoimm. Rev.10, 150–154 (2011).
   PubMedGoogle Scholar
• Manoussakis MN, Boiu S, Korkolopoulou P et al. Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjögren’s syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development. Arthritis Rheum.56, 3977–3988 (2007).
   PubMed Web of Science ®Google Scholar
• Vaudo G, Bocci EB, Schoenfeld Y et al. Precocious intima-media thickening in patients with primary Sjögren’s syndrome. Arthritis Rheum.52, 3890–3897 (2005).
   PubMedGoogle Scholar
• Shanmugam VK, Swistowski DR, Saddic N, Wang H, Stten VD. Comparison of indirect immunofluorescence and multiplex antinuclear antibody screening in systemic sclerosis. Clin. Rheumatol.30, 1363–1368 (2011).
   PubMed Web of Science ®Google Scholar
• Au K, Singh MK, Bodukam V et al. Atherosclerosis in systemic sclerosis: a systemic review and meta-analysis. Arthritis Rheum.63, 2078–2090 (2011).
   PubMedGoogle Scholar
• Mok MY, Lau CS, Chiu SS et al. Systemic sclerosis is an independent risk factor for increased coronary artery calcium deposition. Arthritis Rheum.63, 1387–1395 (2011).
   PubMedGoogle Scholar
• Nguyen C, Berezne A, Baubet T et al. Association of gender with clinical expression, quality of life, disability, and depression and anxiety in patients with systemic sclerosis. PLoS ONE6, e17551 (2011).
   Google Scholar
• Dube SR, Fairweather D, Pearson W, Felitti VJ, Anda RF, Croft JB. Cumulative childhood stress and autoimmune diseases in adults. Psychosom. Med. J. Biobehav. Med.71, 243–250 (2009).
   PubMed Web of Science ®Google Scholar
• Firestein GS. Evolving concepts of rheumatoid arthritis. Nature423, 356–361 (2003).
   PubMed Web of Science ®Google Scholar
• Carson DA, Chen PP, Fox RI et al. Rheumatoid factor and immune networks. Ann. Rev. Immunol.5, 109–126 (1987).
   PubMed Web of Science ®Google Scholar
• Newkirk MM. Rheumatoid factors: host resistance or autoimmunity? Clin. Immunol.104, 1–13 (2002).
   PubMed Web of Science ®Google Scholar
• Dorner T, Egerer K, Feist E, Burmester GR. Rheumatoid factor revisited. Curr. Opin. Rheumatol.16, 246–253 (2004).
   PubMed Web of Science ®Google Scholar
• Christensen P, Schroder AK. Possible role of microbial IgG Fc-binding proteins in rheumatic arthritis. Agents Actions29, 88–94 (1990).
   PubMedGoogle Scholar
• Shoenfeld Y, Rose NR (Eds). Infection and Autoimmunity. Elsevier, Amsterdam, The Netherlands (2004).
   Google Scholar
• Santegoets KCM, van Bon L, van den Berg WB, Wenink MH, Radstake TRDJ. Toll-like receptors in rheumatic diseases: are we paying a high price for our defense against bugs? FEBS Letters585, 3660–3666 (2011).
   PubMed Web of Science ®Google Scholar
• Tomasson G, Aspelund T, Jonsson T, Valdimarsson H, Felson DT, Gudnason V. Effect of rheumatoid factor on mortality and coronary heart disease. Ann. Rheum. Dis.69, 1649–1654 (2010).
   PubMed Web of Science ®Google Scholar
• Goodson NJ, Wiles NJ, Lunt M, Barrett EM, Silman AJ, Symmons DP. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum.46, 2010–2019 (2002).
   PubMed Web of Science ®Google Scholar
• Goodson NJ, Symmons DP, Scott DG, Bunn D, Lunt M, Silman AJ. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum.52, 2293–2299 (2005).
   PubMed Web of Science ®Google Scholar
• Naz SM, Farraqher TM, Bunn DK, Symmons DP, Bruce IN. The influence of age at symptom onset and length of followup on mortality in patients with recent-onset inflammatory polyarthritis. Arthritis Rheum.58, 985–989 (2008).
   PubMedGoogle Scholar
• Mustafa A, Nityanand S, Berglund L, Lithell H, Lefvert AK. Circulating immune complexes in 50-year-old men as a strong and independent risk factor for myocardial infarction. Circulation102, 2576–2581 (2000).
   PubMedGoogle Scholar
• Edwards CJ, Syddall H, Goswami R et al. The autoantibody rheumatoid factor may be an independent risk factor for ischemic heart disease in men. Heart93, 1263–1267 (2007).
   PubMedGoogle Scholar
• Wolfe F, Cathey MA, Roberts FK. The latex test revisited: rheumatoid factor testing in 8,287 rheumatic disease patients. Arthritis Rheum.34, 951–960 (1991).
   PubMed Web of Science ®Google Scholar
• Anaya J-M, Liu GT, D’Souza E, Ogawa N, Luan X, Talal N. Primary Sjögren’s syndrome in men. Ann. Rheum. Dis.54, 748–751 (1995).
   PubMedGoogle Scholar
• Doria A, Pauletto P (Eds). The Heart in Systemic Autoimmune Diseases. Elsevier, Amsterdam, The Netherlands (2004).
   Google Scholar
• Shoenfeld Y, Rose NR (Eds). Infection and Autoimmunity. Elsevier, Amsterdam, The Netherlands (2004).
   Google Scholar